Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

ΜelanoQ: A Consensus Questionnaire of Standardized Epidemiologic and Clinical Variables for Melanoma Risk Assessment by the MelaNostrum Consortium.

Stratigos AJ, Fargnoli MC, De Nicolo A, Peris K, Puig S, Soura E, Menin C, Calista D, Ghiorzo P, Mandala M, Massi D, Rodolfo M, Del Regno L, Stefanaki I, Gogas H, Bataille V, Tucker MA, Whiteman D, Nagore E, Landi MT.

J Eur Acad Dermatol Venereol. 2018 Aug 10. doi: 10.1111/jdv.15208. [Epub ahead of print]

PMID:
30098061
2.

Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma.

Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Calista D, Ghiorzo P, Peris K, Puig S, Menin C, De Nicolo A, Rodolfo M, Pellegrini C, Pastorino L, Evangelou E, Zhang T, Hua X, DellaValle CT, Timothy Bishop D, MacGregor S, Iles MI, Law MH, Cust A, Brown KM, Stratigos AJ, Nagore E, Chanock S, Shi J; Melanoma Meta-Analysis Consortium; MelaNostrum Consortium, Landi MT.

Hum Mol Genet. 2018 Jul 30. doi: 10.1093/hmg/ddy282. [Epub ahead of print]

PMID:
30060076
3.

Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.

Sangalli A, Orlandi E, Poli A, Maurichi A, Santinami M, Nicolis M, Ferronato S, Malerba G, Rodolfo M, Gomez Lira M.

Melanoma Res. 2017 Aug;27(4):309-314. doi: 10.1097/CMR.0000000000000360.

PMID:
28654546
4.

microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.

Vallacchi V, Camisaschi C, Dugo M, Vergani E, Deho P, Gualeni A, Huber V, Gloghini A, Maurichi A, Santinami M, Sensi M, Castelli C, Rivoltini L, Rodolfo M.

Genes (Basel). 2016 Dec 14;7(12). pii: E124.

5.

Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients.

Kohli JS, Tolomio E, Frigerio S, Maurichi A, Rodolfo M, Bennett DC.

J Invest Dermatol. 2017 Mar;137(3):766-768. doi: 10.1016/j.jid.2016.10.026. Epub 2016 Oct 29. No abstract available.

6.

Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer.

Camisaschi C, Vallacchi V, Vergani E, Tazzari M, Ferro S, Tuccitto A, Kuchuk O, Shahaj E, Sulsenti R, Castelli C, Rodolfo M, Rivoltini L, Huber V.

Vaccines (Basel). 2016 Nov 4;4(4). pii: E38. Review.

7.

Melanoma risk alleles are associated with downregulation of the MTAP gene and hypermethylation of a CpG island upstream of the gene in dermal fibroblasts.

Sangalli A, Malerba G, Tessari G, Rodolfo M, Gomez-Lira M.

Exp Dermatol. 2017 Aug;26(8):733-736. doi: 10.1111/exd.13247. Epub 2017 Feb 2.

PMID:
27761950
8.

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo.

Bonner MY, Karlsson I, Rodolfo M, Arnold RS, Vergani E, Arbiser JL.

Oncotarget. 2016 Mar 15;7(11):12857-68. doi: 10.18632/oncotarget.7289.

9.

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, Maurichi A, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Astrua C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto P, Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G.

J Am Acad Dermatol. 2016 Feb;74(2):325-32. doi: 10.1016/j.jaad.2015.09.053.

PMID:
26775776
10.

Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.

Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M.

Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599.

11.

Association of microRNA 146a polymorphism rs2910164 and the risk of melanoma in an Italian population.

Gomez-Lira M, Ferronato S, Orlandi E, Dal Molin A, Malerba G, Frigerio S, Rodolfo M, Romanelli MG.

Exp Dermatol. 2015 Oct;24(10):794-5. doi: 10.1111/exd.12778. Epub 2015 Aug 18. No abstract available.

PMID:
26122011
12.

Association of promoter polymorphism -765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts.

Gomez-Lira M, Ferronato S, Malerba G, Santinami M, Maurichi A, Sangalli A, Turco A, Perego P, Rodolfo M.

Exp Dermatol. 2014 Oct;23(10):766-8. doi: 10.1111/exd.12522.

PMID:
25060715
13.

Immune response markers in sentinel nodes may predict melanoma progression.

Rodolfo M, Castelli C, Rivoltini L.

Oncoimmunology. 2014 Apr 15;3:e28498. eCollection 2014.

14.

Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies.

Castelli C, Rivoltini L, Rodolfo M, Tazzari M, Belgiovine C, Allavena P.

Cancer Immunol Immunother. 2015 Jan;64(1):83-9. doi: 10.1007/s00262-014-1576-1. Epub 2014 Jul 4. Review.

PMID:
24993564
15.

Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.

Gatti L, Sevko A, De Cesare M, Arrighetti N, Manenti G, Ciusani E, Verderio P, Ciniselli CM, Cominetti D, Carenini N, Corna E, Zaffaroni N, Rodolfo M, Rivoltini L, Umansky V, Perego P.

Oncotarget. 2014 Jun 30;5(12):4516-28.

16.

Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment.

Camisaschi C, Vallacchi V, Castelli C, Rivoltini L, Rodolfo M.

Expert Rev Mol Diagn. 2014 Jul;14(6):643-6. doi: 10.1586/14737159.2014.928206. Epub 2014 Jun 10.

PMID:
24914691
17.

A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma.

Frigerio S, Disciglio V, Manoukian S, Peissel B, Della Torre G, Maurichi A, Collini P, Pasini B, Gotti G, Ferrari A, Rivoltini L, Massimino M, Rodolfo M.

BMC Med Genet. 2014 May 17;15:59. doi: 10.1186/1471-2350-15-59.

18.

Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.

Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E, Santinami M, Cabras AD, Arienti F, Triebel F, Rodolfo M, Rivoltini L, Castelli C.

J Invest Dermatol. 2014 Jul;134(7):1893-1902. doi: 10.1038/jid.2014.29. Epub 2014 Jan 17.

19.

Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.

Vallacchi V, Vergani E, Camisaschi C, Deho P, Cabras AD, Sensi M, De Cecco L, Bassani N, Ambrogi F, Carbone A, Crippa F, Vergani B, Frati P, Arienti F, Patuzzo R, Villa A, Biganzoli E, Canevari S, Santinami M, Castelli C, Rivoltini L, Rodolfo M.

Cancer Res. 2014 Jan 1;74(1):130-40. doi: 10.1158/0008-5472.CAN-13-1672.

20.

Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis?

Pollio A, Tomasi A, Seidenari S, Pellacani G, Rodolfo M, Frigerio S, Maurichi A, Turchetti D, Bassoli S, Ruini C, Ponti G.

Pigment Cell Melanoma Res. 2013 Sep;26(5):755-7. doi: 10.1111/pcmr.12122. Epub 2013 Jun 27. No abstract available.

PMID:
23802662
21.

CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients.

Bassoli S, Maurichi A, Rodolfo M, Casari A, Frigerio S, Pupelli G, Farnetani F, Pelosi G, Santinami M, Pellacani G.

Exp Dermatol. 2013 Jun;22(6):411-6. doi: 10.1111/exd.12168.

PMID:
23711066
22.

A variant in FTO shows association with melanoma risk not due to BMI.

Iles MM, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, Harland M, Macgregor S, Taylor JC, Aben KK, Akslen LA, Avril MF, Azizi E, Bakker B, Benediktsdottir KR, Bergman W, Scarrà GB, Brown KM, Calista D, Chaudru V, Fargnoli MC, Cust AE, Demenais F, de Waal AC, Dębniak T, Elder DE, Friedman E, Galan P, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Helsing P, Hočevar M, Höiom V, Hopper JL, Ingvar C, Janssen M, Jenkins MA, Kanetsky PA, Kiemeney LA, Lang J, Lathrop GM, Leachman S, Lee JE, Lubiński J, Mackie RM, Mann GJ, Martin NG, Mayordomo JI, Molven A, Mulder S, Nagore E, Novaković S, Okamoto I, Olafsson JH, Olsson H, Pehamberger H, Peris K, Grasa MP, Planelles D, Puig S, Puig-Butille JA, Randerson-Moor J, Requena C, Rivoltini L, Rodolfo M, Santinami M, Sigurgeirsson B, Snowden H, Song F, Sulem P, Thorisdottir K, Tuominen R, Van Belle P, van der Stoep N, van Rossum MM, Wei Q, Wendt J, Zelenika D, Zhang M, Landi MT, Thorleifsson G, Bishop DT, Amos CI, Hayward NK, Stefansson K, Bishop JA, Barrett JH; GenoMEL Consortium; Q-MEGA and AMFS Investigators.

Nat Genet. 2013 Apr;45(4):428-32, 432e1. doi: 10.1038/ng.2571. Epub 2013 Mar 3.

23.

Promoter methylation of aminopeptidase N/CD13 in malignant melanoma.

Wulfänger J, Schneider H, Wild P, Ikenberg K, Rodolfo M, Rivoltini L, Meyer S, Riemann D, Seliger B.

Carcinogenesis. 2012 Apr;33(4):781-90. doi: 10.1093/carcin/bgs091. Epub 2012 Feb 3.

PMID:
22307972
24.

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, Bongarzone I, Rodolfo M.

Neoplasia. 2011 Dec;13(12):1132-42.

25.

MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.

Caramuta S, Egyházi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui WO.

J Invest Dermatol. 2010 Aug;130(8):2062-70. doi: 10.1038/jid.2010.63. Epub 2010 Apr 1.

26.

pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.

De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Della Mina P, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S.

Int J Cancer. 2010 Jul 1;127(1):207-19. doi: 10.1002/ijc.25009.

27.

Mutational profile of GNAQQ209 in human tumors.

Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M, Marchetti A, Bardelli A.

PLoS One. 2009 Aug 31;4(8):e6833. doi: 10.1371/journal.pone.0006833.

28.

New common variants affecting susceptibility to basal cell carcinoma.

Stacey SN, Sulem P, Masson G, Gudjonsson SA, Thorleifsson G, Jakobsdottir M, Sigurdsson A, Gudbjartsson DF, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Scherer D, Hemminki K, Rudnai P, Gurzau E, Koppova K, Botella-Estrada R, Soriano V, Juberias P, Saez B, Gilaberte Y, Fuentelsaz V, Corredera C, Grasa M, Höiom V, Lindblom A, Bonenkamp JJ, van Rossum MM, Aben KK, de Vries E, Santinami M, Di Mauro MG, Maurichi A, Wendt J, Hochleitner P, Pehamberger H, Gudmundsson J, Magnusdottir DN, Gretarsdottir S, Holm H, Steinthorsdottir V, Frigge ML, Blondal T, Saemundsdottir J, Bjarnason H, Kristjansson K, Bjornsdottir G, Okamoto I, Rivoltini L, Rodolfo M, Kiemeney LA, Hansson J, Nagore E, Mayordomo JI, Kumar R, Karagas MR, Nelson HH, Gulcher JR, Rafnar T, Thorsteinsdottir U, Olafsson JH, Kong A, Stefansson K.

Nat Genet. 2009 Aug;41(8):909-14. doi: 10.1038/ng.412. Epub 2009 Jul 5.

29.

Clinical genetic testing for familial melanoma in Italy: a cooperative study.

Bruno W, Ghiorzo P, Battistuzzi L, Ascierto PA, Barile M, Gargiulo S, Gensini F, Gliori S, Guida M, Lombardo M, Manoukian S, Menin C, Nasti S, Origone P, Pasini B, Pastorino L, Peissel B, Pizzichetta MA, Queirolo P, Rodolfo M, Romanini A, Scaini MC, Testori A, Tibiletti MG, Turchetti D, Leachman SA, Bianchi Scarrà G; IMI, Italian Melanoma Intergroup.

J Am Acad Dermatol. 2009 Nov;61(5):775-82. doi: 10.1016/j.jaad.2009.03.039. Epub 2009 Jun 4.

PMID:
19500876
30.

Molecular profiling of the "plexinome" in melanoma and pancreatic cancer.

Balakrishnan A, Penachioni JY, Lamba S, Bleeker FE, Zanon C, Rodolfo M, Vallacchi V, Scarpa A, Felicioni L, Buck M, Marchetti A, Comoglio PM, Bardelli A, Tamagnone L.

Hum Mutat. 2009 Aug;30(8):1167-74. doi: 10.1002/humu.21017.

31.

Regulatory role of CCN3 in melanoma cell interaction with the extracellular matrix.

Vallacchi V, Rodolfo M.

Cell Adh Migr. 2009 Jan-Mar;3(1):7-10. Epub 2009 Jan 21.

32.

Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.

Daniotti M, Ferrari A, Frigerio S, Casieri P, Miselli F, Zucca E, Collini P, Della Torre G, Manoukian S, Peissel B, Bono A, Santinami M, Parmiani G, Rivoltini L, Pilotti S, Rodolfo M.

J Invest Dermatol. 2009 Jul;129(7):1759-68. doi: 10.1038/jid.2008.422. Epub 2009 Jan 22.

33.

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.

Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A.

Hum Mutat. 2009 Jan;30(1):7-11. doi: 10.1002/humu.20937.

PMID:
19117336
34.

Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes.

Bleeker FE, Lamba S, Rodolfo M, Scarpa A, Leenstra S, Vandertop WP, Bardelli A.

Hum Mutat. 2009 Feb;30(2):E451-9. doi: 10.1002/humu.20927.

PMID:
19058223
35.

RNASET2 as a tumor antagonizing gene in a melanoma cancer model.

Monti L, Rodolfo M, Lo Russo G, Noonan D, Acquati F, Taramelli R.

Oncol Res. 2008;17(2):69-74. Erratum in: Oncol Res. 2008;17(4):191. Rudolfo, Monica [corrected to Rodolfo, Monica].

PMID:
18543608
36.

AKT1(E17K) in human solid tumours.

Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Grammastro MD, Sciarrotta MG, Zanon C, Marchetti A, Bardelli A.

Oncogene. 2008 Sep 18;27(42):5648-50. doi: 10.1038/onc.2008.170. Epub 2008 May 26.

PMID:
18504432
37.

CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.

Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A, Tragni G, Balsari A, Carbone A, Rivoltini L, Parmiani G, Lazar N, Perbal B, Rodolfo M.

Cancer Res. 2008 Feb 1;68(3):715-23. doi: 10.1158/0008-5472.CAN-07-2103. Erratum in: Cancer Res. 2008 Mar 15;68(6):2051.

38.

Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress.

Kuehnle K, Crameri A, Kälin RE, Luciani P, Benvenuti S, Peri A, Ratti F, Rodolfo M, Kulic L, Heppner FL, Nitsch RM, Mohajeri MH.

Mol Cell Biol. 2008 Jan;28(2):539-50. Epub 2007 Nov 5.

39.

High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells.

Mantovani G, Bondioni S, Lania AG, Rodolfo M, Peverelli E, Polentarutti N, Veliz Rodriguez T, Ferrero S, Bosari S, Beck-Peccoz P, Spada A.

Oncogene. 2008 Mar 20;27(13):1834-43. Epub 2007 Oct 1.

PMID:
17906691
40.

Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.

Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, van Tilborg AA, Leenstra S, Zanon C, Bardelli A.

Cancer Res. 2007 Apr 15;67(8):3545-50.

41.

Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.

Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, Pierotti MA, Parmiani G, Rodolfo M.

Int J Cancer. 2007 Jun 1;120(11):2439-44.

42.

MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.

Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11160-5. Epub 2006 Jul 17.

43.

A merging duo in melanoma formation.

Rodolfo M, Pierotti MA, Parmiani G.

J Invest Dermatol. 2005 Dec;125(6):xii-xiii. No abstract available.

44.

DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis.

Di Stasi D, Vallacchi V, Campi V, Ranzani T, Daniotti M, Chiodini E, Fiorentini S, Greeve I, Prinetti A, Rivoltini L, Pierotti MA, Rodolfo M.

Int J Cancer. 2005 Jun 10;115(2):224-30.

45.

Genetic progression of metastatic melanoma.

Rodolfo M, Daniotti M, Vallacchi V.

Cancer Lett. 2004 Oct 28;214(2):133-47. Review.

PMID:
15363539
46.

BRAF alterations are associated with complex mutational profiles in malignant melanoma.

Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M.

Oncogene. 2004 Aug 5;23(35):5968-77.

PMID:
15195137
47.

CTAB-urea method purifies RNA from melanin for cDNA microarray analysis.

Lagonigro MS, De Cecco L, Carninci P, Di Stasi D, Ranzani T, Rodolfo M, Gariboldi M.

Pigment Cell Res. 2004 Jun;17(3):312-5.

PMID:
15140079
48.

Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.

Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C.

Cancer Res. 2003 Oct 15;63(20):6948-55.

49.

Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA.

Sfondrini L, Besusso D, Rumio C, Rodolfo M, Ménard S, Balsari A.

FASEB J. 2002 Nov;16(13):1749-54.

PMID:
12409317
50.

Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice.

Sfondrini L, Besusso D, Zoia MT, Rodolfo M, Invernizzi AM, Taniguchi M, Nakayama T, Colombo MP, Ménard S, Balsari A.

J Immunol. 2002 Jul 1;169(1):151-8.

Supplemental Content

Loading ...
Support Center